Clinical trial
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
NCT00144508 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00144508 |
|---|---|
| Title | Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA) |
| Official title | An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug, Other |
| Interventions | MRA (Tocilizumab), current treatment |
| Enrollment | 306 |
| Start date | Mar 1, 2003 |
| Primary completion | May 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Sep 5, 2005 |
| Last update posted | Feb 2, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: